- Home
- Applications
- in vitro skin models
Refine by
In Vitro Skin Models Product Applications
5 applications found
BOC Sciences is committed to supplying cost-effective products and services. We provide Ceftriaxone Sodium (Cas No:74578-69-1). More information, please visit the website: http://www.bocsci.com/ceftriaxone-sodium-cas-74578-69-1-item-97893.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
Microbiotica is using best-in-class clinical data and sample sets coupled with its unrivalled microbiome profiling capability to progress best-in-class therapeutics and biomarkers. Microbiotica has programs in IBD, Immuno-oncology and Gut Epithelial Barrier Repair developing medicines and biomarkers based on microbiota. These programs start with deep metagenomic and culture-based analysis of patient samples and involve advanced bioinformatics and machine learning, to identify highly significant bacterial ...
ByMicrobiotica Limited based in Little Chesterford, UNITED KINGDOM
Sound-induced endothelial cell condensation leads to the formation of stable vascular structures. ...
BymimiX Biotherapeutics based in Biel/Bienne, SWITZERLAND
Isolating edited-pluripotent stem cells with traditional sorting techniques can subject the cells to rough conditions in which gene expression, genomic stability and overall cell-health can become compromised. Microfluidic cell sorting with the WOLF, along with single cell deposition using the N1 single cell dispenser, eliminates the challenges that pluripotent stem cells face by sorting at gentle pressures without decompression shock and shear stress, and allow for efficient single cell deposition for high ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)
Increase clinical translation with Organ-Chips for ADME-Tox assessments. Accurate ADME-Tox profiling of preclinical drug candidates remains a challenge. Preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies are pivotal to predicting human response. However, approximately 30% of drugs fail during human clinical trials due to adverse reactions despite promising preclinical study results, and another 60% fail due to lack of efficacy. As companies broaden the modality toolbox ...
ByEmulate based in Boston, MASSACHUSETTS (USA)